Jaw osteonecrosis in patients treated with denosumab 120 mg with regular dental monitoring: 4-year retrospective study | Journal of Oral Medicine and Oral Surgery

Open Access

Table II

Patients' baseline characteristics.

		n	%
Sex	Men	68	27
	Women	183	73
Age (years)	Median Min − Max Q1 − Q3	63 26 − 91 54 − 71.5
Primary cancer	Breast	165	65.7
	Prostate	42	16.7
	Lung	12	4.8
	Kidney	7	2.8
	GCT*	5	2.0
	Other†	20
Cancer treatment	Hormone therapy‡	175	69.7
	Chemotherapy	119	47.4
	PKI TKI	94	37.5
	Included Palbociclib	86
	Immunotherapy§	26	10.4
	Anti-angiogenic drugs¶	28	11.2
Comorbidity	Corticosteroids	49	19.5
Comorbidity	Diabetes mellitus	9	3.6
	Tobacco	8	3.2
	Anemia	4	1.6

Treatments and groups are not mutually exclusive, patients could receive one or more treatments.

*GCT : Giant-Cell Tumor of bone.

PKI: Protein kinase inhibitors; TKI: Tyrosine kinase inhibitors.

†Other primary cancer: colon (3), bladder (3), thyroid (3), endometrium (2), testis (1), rectum (1), pancreas (1), esophagus (1), melanoma (1), nasopharyngeal (1), cervix (1), ethmoid sinus (1), not found (1).

‡Main treatments (>2% of patients): letrozole (75), fulvestrant (42), enzalutamide (17), abiraterone acetate (18), leuprorelin acetate (15), tamoxifen (14), triptorelin (13), exemestane (11), degarelix acetate (7), anastrozole (6).

§Main treatments (>2% of patients): trastuzumab (12), pertuzumab (7), nivolumab(7).

¶Anti-angiogenic drugs: everolimus (14), sunitinib malate (3), pazopanib hydrochloride (2), cabozantinib malate (2), bevacizumab (7).

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.